Tirzepatide

Dual GIP/GLP-1 receptor agonist for superior weight loss

4.7
3 avis

Rating Breakdown

Weight Loss Efficacy
5.0
Appetite Suppression
4.7
Metabolic Improvement
5.0
Body Composition
4.7
Glycemic Control
4.3
Safety & Side Effects
4.0
Cardiovascular Benefit
3.7
Dosing Convenience
5.0

Aperçu

Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist. It produces greater weight loss than semaglutide by targeting two incretin pathways simultaneously.

Key Information

Identity
Also Known As Zepbound; Mounjaro
Sequence Modified GIP/GLP-1 dual agonist
CAS Number 2020348-31-6
Molecular Formula C225H348N52O68
Properties
Half-Life 5 days
Administration subcutaneous injection
Dosage Range 2.5-15 mg weekly
Price Range $3.5–$30.0/mg
Handling & Storage
Storage Refrigerated 2-8C
Reconstitution Pre-filled pen, no reconstitution needed
Regulatory Status
US Status FDA-approved
Legal Status FDA-approved as Zepbound (weight) and Mounjaro (diabetes).
Research Papers 1 indexed

Mechanism

Dual agonism of GIP and GLP-1 receptors, providing enhanced appetite suppression and improved insulin sensitivity compared to GLP-1-only agonists.

Benefits

  • Up to 22.5% weight loss
  • Dual GIP/GLP-1 mechanism
  • Superior to semaglutide
  • Weekly dosing

Side Effects

  • Nausea
  • Diarrhea
  • Vomiting
  • Decreased appetite

Contraindications

  • Medullary thyroid carcinoma
  • MEN2 syndrome
  • Pregnancy

Evidence Summary

SURMOUNT trials showed up to 22.5% weight loss at 72 weeks.

Research

SURMOUNT trials showed up to 22.5% weight loss at 72 weeks, significantly outperforming semaglutide in head-to-head comparisons.

View Research

Safety

Similar GLP-1 class side effects: nausea, diarrhea, vomiting. Boxed warning for thyroid C-cell tumors.

Legal Status

FDA-approved as Zepbound (weight) and Mounjaro (diabetes).

Recherche

1 research papers indexed

View Research

Write a Review

Rating Breakdown

Effectiveness
5.0
Safety
4.0
Value
4.0
Overall
4.7

Based on 3 avis.

Avis

22 lbs down in 4 months 2026-07-29
Jessica A.

Tirzepatide is a beast. Lost 22 lbs in 4 months. Better than semaglutide in my experience - less nausea, more energy. The dual GIP/GLP-1 mechanism really makes a difference.

Effectiveness: 5/5 Safety: 4/5 Value: 4/5
Superior to semaglutide 2026-06-01
Jessica A.

Switched from semaglutide after stalling. Tirz broke through my plateau - another 12 lbs in 2 months. Side effects are similar but milder. Worth the extra cost.

Effectiveness: 5/5 Safety: 4/5 Value: 4/5
Best weight loss peptide available 2026-04-16
Jessica A.

After trying everything, tirzepatide finally worked. 28 lbs in 5 months. The appetite suppression is unmatched. Weekly dosing makes it easy to stick with.

Effectiveness: 5/5 Safety: 4/5 Value: 4/5